Medical Marijuana, Inc. owns appx. 45.5% of AXIM® Biotechnologies.
AXIM® Biotechnologies is an innovative biotechnology company focusing on the research, development, and production of cannabinoid-based pharmaceuticals, nutraceuticals, and supplements with offices in New York City and The Netherlands.
AXIM® Biotechnologies was created in November of 2010. The company owns an impressive intellectual property portfolio – with 5 issued patents, 12 pending patents, and 28 trademarks.
As part of its IP portfolio, AXIM® owns the patent for chewing gum as a delivery method for cannabinoids, which it has developed into several separate consumer products and potential new drugs.
CBD-only Canchew® gum is marketed as a wellness product and is available to purchase wherever CBD hemp oil products are sold.
In addition to their consumer products, AXIM® Biotechnologies, Inc. is in phase 3 clinical trials for their combination CBD/THC (tetrahydrocannabinol) gum, MedChew® Rx, for the treatment of pain and spasticity associated with multiple sclerosis. In August of 2018, the company received outstanding results in stability and dissolution testing on MedChew® Rx. These tests show over 90% availability of the active ingredients in the drug’s current formulation. Once approved by the European Medicines Agency (EMA), the gum will be offered across the European Union.
The company is also developing MedChew® w/ dronabinol – aimed at treating nausea, vomiting, and loss of appetite linked to chemotherapy and AIDS. The main active ingredient, dronabinol, is a synthetic THC-like compound already approved by the FDA for the same indications.
AXIM® recently entered an agreement with QPS Netherlands BV, a contract research organization (CRO), in order to conduct a bio comparison study to determine the bioavailability of dronabinol when formulated into a chewing gum delivery system.
The company’s CanChew® Rx, formulated with natural CBD, is being developed for drug-related psychosis. The same CRO conducting studies on MedChew® w/dronabinol will also conduct an open-label, randomized, 3 period crossover pharmacokinetic study on AXIM’s CanChew® Rx product.
The company’s fourth new drug program is MedChew® RL for restless leg syndrome. The company is currently in the opening phases of this drug program. The company has partnered with an Israel based CRO to conduct proof of concept studies on AXIM®’s CBD and Gabapentin chewing gum product.
More recently, AXIM® Biotechnologies has also started trials for a new cannabigerol (CBG) based ointment for the treatment of psoriasis and atopic dermatitis, commonly known as eczema. Their patented AX-1602 proprietary ointment is being tested in a placebo controlled study to best judge its efficacy for these two dermatological indications.
The company received its patent in March of 2019 on a method to treat atopic dermatitis, also known as eczema, using a topical cream containing cannabinoids – specifically cannabidiol CBD and CBG.
In addition to AXIM® Biotechnologies CBD products, AXIM® is also expanding its use of CBG in a new line of oral care products, Oraximax™. Designed for the daily user, these consumer product brands capitalize on hemp’s mix of phytocannabinoids and nutrients in their proprietary formulas. In January of 2019, the company was awarded a patent for its oral care composition containing cannabinoids, including CBD and CBG.
The company also received a patent in October of 2018 for suppository formulations comprised of cannabinoids. The company’s proprietary suppository composition is formulated for easy absorption through the mucosal membrane, allowing for useful administration of cannabinoids in patients with pain, nausea, vomiting, and other conditions preventing swallowing. AXIM plans to utilize this formulation for use in its clinical program that aims to treat gastrointestinal (GI) conditions such as postoperative ileus and/or Inflammatory Bowel Disease (IBD), Irritable Bowel Syndrome (IBS), and others.
The company’s manufacturing methods meet compliance and quality standards according to the cGMP, FDA, and EMA. AXIM® was awarded cGMP certification for extraction and purification of cannabinoid APIs in Europe and has Medical Ethical Committee approval on human trials using proprietary formulations.
In February of 2019, AXIM® successfully executed its proprietary method for extraction and encapsulation of high purity cannabinoids for use in formulating their products. This process, patented for the extraction of THC, utilizes the company’s cGMP methods to create high quality pharmaceutical ingredients.
With several new drugs in clinical trials and many new products in the pipeline, AXIM® is strongly positioned for growth in cannabinoid-based treatments. AXIM® Biotechnologies sets the standard for cannabinoid bioscience through the discovery and commercialization of new materials and technologies for healthy living.
Visit the AXIM® Biotechnologies website to learn more.
NEWS & PRESS
› Owns the patent for chewing gum as a delivery method for cannabinoids. Read more.
› Owns and has successfully applied proprietary method for extracting and encapsulating high purity cannabinoid molecules. Read more.
› In clinical trials for MedChewRX for pain and spasticity in multiple sclerosis patients. Read more.
› Conducting studies on MedChew® w/ dronabinol to test best formulation and bioavailability of its active ingredients. Read more.
› Proof of concept trials underway for patented AX-1602 proprietary ointment for the treatment of eczema and psoriasis. Read more.
Latest AXIM® Biotechnologies News
Medical Marijuana, Inc. Investment Company AXIM® Biotechnologies Completes Acquisition of Oncology Research and Development Company Sapphire Biotech, Inc.Read more
Medical Marijuana, Inc. Investment Company AXIM® Biotechnologies to Acquire Leading Oncology Research and Development Company Sapphire Biotech, Inc.Read more
Medical Marijuana, Inc. Major Investment Company AXIM® Biotechnologies Begins GMP Manufacturing Of Cannabinoid-Based Gum With Dronabinol For Use In Upcoming Clinical StudiesRead more
John W. Huemoeller II: Chief Executive Officer
Mr. Huemoeller has over 35 years experience in investment banking, finance, sales and marketing. Mr. Huemoeller began his career as an investment advisor in 1982 with M.L. Stern & Company a municipal bond firm in California and became a registered principal in 1985. He has previously been registered with various state insurance boards, as well as with the Chicago Board of Trade as a commodities broker. Mr. Huemoeller has worked for Smith Barney, Drexel Burnham, Prudential Securities, and Paine Webber and has extensive experience in stocks, bonds, commodities, mergers and acquisitions, leveraged buyouts and private placement transactions.
Dr. George E. Anastassov MD, DDS, MBA: Founder | Chairman of the Board
Dr. George E. Anastassov is the Founder of AXIM Biotechnologies, Inc. and Chairman of the Board. Prior to that Dr. Anastassov was one of the founders and the CEO of CanChew Biotechnologies, LLC in 2012. Dr. Anastassov is also one of the founders and a Board Member and a general partner of Sanammad Foundation and Sanammad Pharmaceuticals; both companies originated and located in The Netherlands since 2009 and 2014, respectively. He is one of the developers of the first-in-the-world cannabinoid-containing chewing gum-based delivery system.
Dr. Anastassov possesses Medical and Dental Doctorates as well as an Executive MBA. Dr. Anastassov has been recognized in “Who’s Who in Medicine” as well as “Who’s Who in Business Professionals” numerous times. He is the recipient of multiple national and international professional and humanitarian awards. Dr. Anastassov has been actively involved in Research and Development in Medicine and Biotechnologies since 1987.
Dr. Philip A. Van Damme DMD, MD, PhD: Chief Medical Officer
Dr. Philip. A. Van Damme is Chief Scientific/Medical Officer of AXIM Biotechnologies Inc., as of May 2014. Prior to that, Dr. Van Damme was one of the founders and CSO of CanChew Biotechnologies LLC, in 2012. He is also one of the founders and President/Director of Sanammad Foundation and Sanammad Pharmaceuticals, both originated and located in The Netherlands since 2009 and 2014, respectively. He is one of the developers of the first-in-the-world cannabinoid-containing chewing gum-based delivery systems. Dr. Van Damme possesses Dental and Medical Doctorates as well as a PhD in Medical Sciences, and has been actively involved in Research and Development in Dentistry, Medicine and Biotechnologies since 1983.
Lekhram Changoer MSc, BSc: Chief Technology Officer
Lekhram Changoer is the Chief Technology Officer of AXIM Biotechnologies, Inc. as of May 2014. He holds a Bachelor’s Degree in Analytical/Organic Chemistry and a Master’s Degree in Organic Chemistry. He was one of the founders of CanChew Biotechnologies, LLC in 2012 and is board member and partner of Sanammad Foundation and Sanammad Pharmaceuticals BV; both companies originated and located in The Netherlands since 2009 and 2014, respectively. He is the originator of multiple patents including patent-pending technology on chewing gum compositions comprising cannabinoids, together with his Sanammad partners. He has over 20 years of experience in the area of Sales & Marketing, R&D, product development, and quality assurance of technical, consumer healthcare and pharmaceutical products – all servicing European and other international markets. During his career he has co-founded different intellectual property-based pharmaceutical and dental companies in different stages from clinical development to the global sales of registered products.
This first in the world, patented cannabinoid-based gum is derived from high-CBD hemp oil. Manufactured in the U.S. and legal in all 50 states, sugar-free mint flavored CanChew® gum is an efficient and reliable method of absorbing CBD hemp oil. Each piece of CanChew® contains 50 mg of hemp oil and 10 mg of CBD.
AXIM Biotech is currently in clinical trials for their combined CBD and THC delayed-release gum, MedChew® RX, for the pain and spasticity associated with multiple sclerosis. Once approved by the European Medicines Agency (EMA), the gum will be offered across the European Union.
MedChew® w/dronabinol is aimed at treating nausea, vomiting, and loss of appetite linked to chemotherapy and AIDS. The main active ingredient, dronabinol, is a synthetic THC-like compound already approved by the FDA for the same indications. AXIM® is conducting a bio comparison study to determine the bioavailability of dronabinol when formulated into a chewing gum delivery system.
MedChew® RL is being developed for relief of the symptoms of restless leg syndrome. The company is currently in the opening phases of this drug program and has partnered with an Israel based CRO to conduct proof of concept studies on AXIM®’s CBD and Gabapentin chewing gum product.
CanChew® Rx, formulated with natural CBD, is being developed for drug-related psychosis. AXIM® is preparing to conduct an open-label, randomized, 3 period crossover pharmacokinetic study on AXIM’s CanChew® Rx product to test how the drug’s active ingredients are absorbed, distributed, and processed by the body.
AXIM Biotechnologies’ patent-pending dental hygiene line, based on Cannabigerol (CBG), will target both daily use oral care and the resolution of oral infections and gum disease. AXIM has selected CBG for its suggested anti-inflammatory and antibacterial properties to protect against the daily trauma caused to the mouth through chewing, speaking, and buildup of infectious organisms.
AXIM’s hemp oil derived rejuvenating skin care line, Renecann™ cannabinoid based hair and skin products will be developed for the discerning daily use customer. Capitalizing on the cannabinoids, essential amino acids, and vitamins and minerals available in hemp oil, the line will contain products like anti-aging cream, lip balm, diaper rash cream, and anti-acne lotion.
AX-1602 is AXIM Biotechnologies’ patent-pending topical ointment for psoriasis and eczema, formulated with cannabigerol (CBG) and other cannabinoids. AXIM’s CBG ointment will be tested in a placebo controlled study to best judge its efficacy before moving into phase I trials.